Home › Rheumatoid Arthritis › NCT05003934
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for the Treatment of Rheumatoid Arthritis
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of Rheumatoid Arthritis * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant Abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur
About the study
This trial will study the safety and efficacy of intravenous infusion and intra-articular injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Rheumatoid Arthritis
What is being tested
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Nov 7, 2021
Contact the study team
Official record on ClinicalTrials.gov — NCT05003934
Locations in the U.S.
| Florida | Prodromos Stem Cell Institute, Naples |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.